Sunshine Biopharma, Inc. SBFM
At closeNov 4, 2026, 5:36 AM EST
Pre-market · Nov 4, 5:36 AM ET
- YTD
- -98.89%
- 1 year
- -99.20%
- Market cap
- 2.09M
- Revenue (ttm)
- 32.96M
- Profit margin
- -12.82%
- EPS (ttm)
- -189.00
- Shares out
- 2.00M
- Forward P/E
- 0.02
- YTD return
- -98.89%
- 1-year return
- -99.20%
- Volume
- 54.16K
- Avg volume
- 305.32K
- Open
- 2.70
- Previous close
- 2.75
- Day's range
- 2.67 – 2.87
- 52-week range
- 2.58 – 464.00
- Beta
- -1.04
- Price target
- 300.00 (+10848.9%)
2Y -575.26 (-99.53%)
Key statistics
- Enterprise value
- -6.08M
- PEG ratio
- 0.00
- Price / sales
- 0.18
- Price / book
- 0.24
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 41.60%
- Free cash flow
- -12.84M
- Total cash
- 12.21M
- Total debt
- 556.55K
- Return on equity
- -17.98%
- Short % of float
- 27.81%
- 50-day average
- 2.80
- 200-day average
- 25.68
Analyst view
- Strong buy0
- Buy1
- Hold0
- Sell0
- Strong sell0
Next earnings
Consensus EPS estimate 0.00.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 5, 2024 | Sep 1, 2024 | 0.00 | -0.94 | — | — |
| Aug 16, 2024 | Jun 1, 2024 | 0.00 | -9.94 | — | — |
| May 20, 2024 | Mar 1, 2024 | 0.00 | -40.00 | — | — |
| Mar 28, 2024 | Dec 1, 2023 | 0.00 | -100.00 | — | — |
| Nov 13, 2023 | Sep 1, 2023 | 0.00 | -80.00 | — | — |
| Aug 11, 2023 | Jun 1, 2023 | 0.00 | -40.00 | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 5, 2024 | Aegis Capital | reit | Buy | Buy |
| Aug 7, 2023 | Aegis Capital | init | — | Buy |
About Sunshine Biopharma, Inc.
Sunshine Biopharma, Inc., a pharmaceutical company, focuses on the research and development of life-saving medicines in various therapeutic areas, including oncology and antivirals in the United States and Canada. It operates in two segments, Prescription Generic Pharmaceuticals and Nonprescription Over-The-Counter Products. The company is developing SBFM-PL4, a protease inhibitor for the treatment of SARS coronavirus infections; Adva-27a, a small chemotherapy molecule to treat pancreatic cancer; and K1.1 mRNA, a lipid nano-particle for liver cancer. It also offers Essential 9, an amino acids capsules; Calcium-Vitamin D supplement under the Essential Calcium-Vitamin D brand name; and L-Citrulline and Taurine products. In addition, the company provides various generic prescription drugs for osteoporosis, cardiovascular, antipsychotic, antibacterial, hypertension, anti-inflammatory, allergy, antibiotic, central nervous system, diabetes, urology, antifungal, antimalarial, oncology, gastroenterology, and anticonvulsant indications. Sunshine Biopharma, Inc. is based in Fort Lauderdale, Florida.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Country
- United States
- Website
- sunshinebiopharma.com
News
12 Health Care Stocks Moving In Thursday's Intraday Session 
12 Health Care Stocks Moving In Tuesday's Intraday Session 
12 Health Care Stocks Moving In Friday's Intraday Session - 12 Health Care Stocks Moving In Thursday's Intraday Session
Crude Oil Gains 5%; PepsiCo Posts Upbeat Q3 Earnings 
Dow Falls Over 100 Points; US Initial Jobless Claims Decline - 12 Health Care Stocks Moving In Thursday's Pre-Market Session
- 12 Health Care Stocks Moving In Wednesday's Intraday Session
- 12 Health Care Stocks Moving In Tuesday's After-Market Session
- 12 Health Care Stocks Moving In Monday's Intraday Session
Your note
Sign in to keep a note on SBFM — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| MERZOUKI ABDERRAZZAK | Chief Operating Officer | Stock Award(Grant) | Jan 5, 2021 | 23,342,500 |
| SEBAALY CAMILLE | Chief Financial Officer | Purchase | Nov 29, 2022 | 174,465 |
| SLILATY STEVE N | Chief Executive Officer | Stock Award(Grant) | Jan 5, 2021 | 23,343,500 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Bank of America Corporation | 1.72% | 34,480 | 103.44K | Sep 29, 2024 |
| Nordwand Advisors, LLC | 0.03% | 500 | 1.50K | Sep 29, 2024 |
| Rise Advisors, LLC | 0.00% | 1 | 3 | Sep 29, 2024 |
| Farther Finance Advisors, Llc | 0.00% | 1 | 3 | Sep 29, 2024 |
| National Bank of Canada/FI | 0.00% | 7 | 21 | Sep 29, 2024 |
| Federation Des Caisses Desjardins Du Quebec | 0.00% | 1 | 3 | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity NASDAQ Composite Index Fund | 0.00% | 11 | 33 | Aug 30, 2024 |